Acamar Partners Acquisition Corp. (ACAMU) Files for $300 SPAC IPO
by Kristi Marvin on 2019-01-08 at 11:29am

This morning, we had 2019’s SPAC #7 file for a $300 million IPO in the form of Acamar Partners Acquisition Corp. (ACAMU).  Acamar is being led by Juan Carlos Torres Carretero, as Chairman, and Luis Ignacio Solorzano Aizpuru, as CEO.  Mr. Torres is currently the Executive Chairman of Dufry AG (“Dufry”), the world’s largest travel retailer by revenue.  Additionally, both Mr. Torres and Mr. Solorzano held key positions at Advent International, a global private equity firm; Mr. Torres is the former Managing Partner and Co-Chief Executive Officer of Advent Latin American Private Equity Fund, and Mr. Solozano is the former head of the Mexico office and former Chairman of the Latin America’s Investment Committee.

Acamar intends to focus on the consumer and retail sectors in North America and Western Europe, a sweet spot for a team that has a strong track record in these areas. However, this is a new team, without SPAC experience, and they are debuting in a very tough SPAC climate.  So let’s take a look at the terms:

Acamar terms

These terms are clearly meant for an A+ team.   It’s a straight up 100% in trust, 1/3 warrant, 24 months deal – no “cute play” on extensions or wording. However, there are two items that do stand out.  First, the limit on redemption rights of 10% is a level I can’t remember the last time I’ve seen.  Typically, it’s 15% or 20%, but 10% is aggressive.   Second, once again, we are also seeing the warrant call for shares term, most recently added to RMG Acquisition Corp. (also a Deutsche Bank deal). Some investors may disagree, but I like this feature for the simple reason that you’re getting a fair price for those warrants (using a black scholes model that appears to be using a high volatility) in a market where there isn’t much interest in warrants right now.  Sure, you lose some optionality, but you also lock in a fair price. Which is better in this market?

All told, these terms are aggressive and this is an unproven SPAC team.  However, they do have Goldman Sachs and Deutsche Bank underwriting, so do not expect these terms to change.  Regardless, it’s a good sign that tier-1 deals are still getting filed given the current SPAC conditions and it should be interesting to see if Acamar removes the delaying amendment in their next filing.  If so, count 20 days forward and expect them to price (assuming we’re still in government shutdown mode).

Goldman Sachs and Deutsche Bank are bookrunners.
Ellenoff Grossman & Schole LLP and Skadden, Arps, Slate, Meagher & Flom LLP are issuer’s counsel and underwriter’s counsel, respectively.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved